Loading...
Predictors of Successful Carbidopa/Levodopa Sustained-Release Use in Parkinson's Disease - A Real-World Retrospective Analysis
Purvee, Caleb
Purvee, Caleb
Citations
Altmetric:
License
License
Abstract
Parkinson’s Disease (PD) patients are commonly treated with a regimen of carbidopa/levodopa to control Parkinsonian motor symptoms. These treatments typically begin with carbidopa/levodopa (CD-LD) immediate release (IR) or controlled release (CR). When treating disease progression, it may be advantageous to convert to CD-LD extended release (ER), available exclusively under the brand name Rytary. In this retrospective real-world study, we analyzed whether patients who were recommended to start Rytary and were able to successfully obtain prior authorization, insurance coverage, and payment for Rytary, and both the subsequent efficacy of dose conversion from CD-LD IR or CR to CD-LD ER and adherence in PD patients. The findings of this study will elucidate the factors that have impacted the logistical and clinical success of conversion to Rytary in our population, and will be of interest to the PD community, including clinicians, researchers, advocates, and people with PD. Our results will reveal the factors that hinder the acquisition of Rytary in patients, and the steps in the dose conversion process that prove unsuccessful. These results will prove valuable to clinicians, possibly having a direct impact on patterns of clinical care, with data that advocates for patients’ affordable access to beneficial therapies.
Description
Date
2026-05-08
Student Status
Journal Title
Journal ISSN
Volume Title
Type of presentation
Files
Loading...
Caleb Purvee Thesis.pdf
Adobe PDF, 1.23 MB
Research Projects
Organizational Units
Journal Issue
Citation
DOI
Advisor(s)
Department
Neurological Sciences